Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Has Consensus Target Price of $38.86 According to Analysts

Posted by Brenda Bartman on Oct 5th, 2026

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) has been assigned an average rating of “Buy” from the ten analysts that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $38.86.

Several research firms have commented on AMLX. Guggenheim upped their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Thursday, August 27th. HC Wainwright raised their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Wolfe Research upgraded shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 17th. Finally, Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th.

View Our Latest Research Report on AMLX

Insider Buying and Selling

In other news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Camille L. Bedrosian sold 10,028 shares of Amylyx Pharmaceuticals stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.40, for a total value of $324,907.20. Following the transaction, the insider directly owned 278,064 shares of the company’s stock, valued at $9,009,273.60. This trade represents a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 45,374 shares of company stock valued at $1,259,057. 10.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at about $157,000. Arizona State Retirement System lifted its holdings in shares of Amylyx Pharmaceuticals by 9.5% in the second quarter. Arizona State Retirement System now owns 19,825 shares of the company’s stock valued at $356,000 after purchasing an additional 1,726 shares in the last quarter. Corient Private Wealth LP purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $1,065,000. Alyeska Investment Group L.P. acquired a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $18,912,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Amylyx Pharmaceuticals by 10.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock valued at $3,114,000 after purchasing an additional 16,318 shares during the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Price Performance

AMLX opened at $27.79 on Friday. The business’s 50 day moving average is $29.64 and its two-hundred day moving average is $20.60. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -19.43 and a beta of -0.10. Amylyx Pharmaceuticals has a 52 week low of $10.83 and a 52 week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Equities analysts expect that Amylyx Pharmaceuticals will post -1.48 EPS for the current fiscal year.